Micronized progesterone, progestins, and menopause hormone therapy.
Women Health
; 61(1): 3-14, 2021 Jan.
Article
em En
| MEDLINE
| ID: mdl-32957843
ABSTRACT
Treatment with estrogens alone in women without a uterus or in combination with progestins (PG) in women with a uterus is the most effective treatment for vasomotor symptoms in the peri or postmenopausal period. However, PGs differ by their biological activities, and it is likely that not all PGs will display a class effect. The type of PG is important regarding tolerance and cardiovascular and breast cancer risk. Some studies indicate that micronized progesterone (P) is safer than synthetic PGs with an acceptable metabolic profile. For that purpose, we conducted a narrative review on the balance between benefit/risk using P versus PGs in menopause hormone therapy (MHT) to aid clinician to choose the best regimens, specifically the PG component of hormone therapy, for women with bothersome menopausal symptoms and with a uterus.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Progestinas
/
Progesterona
/
Neoplasias da Mama
/
Terapia de Reposição Hormonal
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article